In an interview with CNBC-TV18, Prashant Nair, Director & Deputy Head of Research, Citi India gives his outlook on the pharma sector. He picks Ranbaxy, Lupin, Apollo Hospital and Ipca as preferred stocks and believes, they will outperform not just the market but also its peers from the pharma space.
first published: May 31, 2012 02:21 pm
A collection of the most-viewed Moneycontrol videos.

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss

Nifty’s Best Case Target & Top Stock Bets For 2026| IPO Wave Set To Get Bigger| Opening Bell Live
You are already a Moneycontrol Pro user.

